FMT Doesn’t Improve Quality of Life for Recurrent C. diff, VA Trial Finds

Fecal microbiota transplantation (FMT, transferring processed stool from a healthy donor into a patient's gut to restore a disrupted bacterial community) has a reputation as one of gut medicine's clearest success stories, credited with curing patients stuck in repeat cycles of Clostridioides difficile infection (C. diff, a bacterial infection that causes severe, recurring diarrhea) when antibiotics alone keep failing. A new preprint from a large Veterans Affairs (VA) trial puts a hard number on something that reputation has mostly skipped over: how much better patients actually feel afterward. The answer, in this trial, is not measurably better at all. The same VA trial had already shown FMT capsules did not even beat a placebo capsule at stopping the infection from coming back. Together, the two results are a reminder that a treatment that sounds like it should work and a treatment that measurably helps a patient's day-to-day life are two different questions, and this study answers both with a no.

Key takeaways

• In a 153-person, double-blind VA trial (the MATCH trial), fecal microbiota transplant (FMT) capsules did not reduce recurrent C. diff infection any better than a placebo capsule: 32.9 percent of the FMT group had a recurrence or died within 56 days, versus 29.9 percent of the placebo group.
• The same trial's newly reported quality-of-life analysis found no meaningful difference between the FMT and placebo groups 56 days after treatment (average quality-of-life score change of 8.0 points for FMT versus 12.6 points for placebo).
• This is a preprint that has not yet been peer-reviewed, and quality of life was a secondary, exploratory measure, not the trial's main question.
• The result does not apply to two newer, FDA-approved fecal microbiota products, which showed both infection-fighting and quality-of-life benefits in their own separate trials.

VA Trial Finds No Quality-of-Life Benefit From FMT Capsules

A new analysis of the 153-person VA trial known as MATCH (Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. difficile at Home) found that patients who received a fecal microbiota transplant capsule for recurrent C. diff infection reported no better quality of life at day 56 than patients who received an identical-looking placebo capsule. Researchers used the Gastrointestinal Quality of Life Index (GIQLI, a validated questionnaire that scores how gut symptoms affect physical, emotional, social and daily functioning, where a higher score means better quality of life) at the start of the trial and again 56 days later. The average improvement in overall score was 8.0 points in the FMT group versus 12.6 points in the placebo group, a difference of -4.6 points with a 95 percent confidence interval of -11.1 to 1.8, meaning the gap is small enough that it could simply be due to chance. Scores covering emotional, physical, social, and "therapeutic influence" domains showed the same pattern: no meaningful difference between the two groups.

This is the same trial that, in results published separately in the journal Clinical Infectious Diseases, already found FMT capsules did not reduce the C. diff infection itself any better than placebo, with a combined outcome of recurrence or death occurring in 32.9 percent of the FMT group versus 29.9 percent of the placebo group (a difference the researchers called not statistically significant). The quality-of-life preprint is a secondary analysis of that same double-null result, asking whether the treatment at least made people feel better day to day even without preventing the infection from returning. It did not.

Why Recurrent C. diff Patients Should Care

C. diff is a major public health problem in its own right: the Centers for Disease Control and Prevention (CDC) estimates roughly 450,000 infections and tens of thousands of associated deaths in the United States each year, and about 20 to 30 percent of patients go on to have at least one recurrence. Recurrent C. diff (rCDI) is not just an inconvenience; the study's authors describe it as a debilitating condition with "severe effects on physical, psychological, social, and professional functioning," which is exactly why a patient-reported quality-of-life measure was built into the trial in the first place. People managing rCDI, and the doctors treating them, often reach for FMT specifically because it is assumed to restore not just gut function on paper but how a person actually feels. This trial, conducted in a largely older population (average age 66.5, with the oldest patients concentrated in the FMT arm), is a direct test of that assumption in the most rigorous format available: a randomized, double-blind, placebo-controlled design rather than an open-label study where patients and doctors know who got the real treatment.

Inside the Double-Blind, Placebo-Controlled MATCH Trial

The MATCH trial enrolled 153 Veterans (76 assigned to FMT, 77 to placebo) between October 2018 and July 2022, drawing patients from 47 facilities across 40 U.S. states, with 37 percent of participants living in rural or highly rural areas. Everyone had a history of at least one prior recurrent C. diff episode (22.2 percent had two or more), and all had already completed a course of antibiotics before receiving either an FMT capsule or a placebo capsule in a 1-to-1 ratio. The study population was 86.2 percent male and 94.6 percent White, reflecting the VA patient base it was drawn from. Quality of life was assessed via the GIQLI at baseline and 56 days later, and there was no loss to follow-up at that endpoint, an unusually clean data set for a trial run across dozens of sites. One notable wrinkle: for the GI-symptom-specific portion of the questionnaire, the placebo group improved significantly more than the FMT group (a change of 6.1 points versus 2.3 points, with a confidence interval of -7.3 to -0.4 that does not cross zero), the one comparison in the entire analysis that reached statistical significance, and it favored placebo, not FMT.

What This Means If You've Had Recurrent C. diff

If you or someone you care for is considering FMT for recurrent C. diff, this trial is a useful reality check rather than a reason to rule the approach out entirely. It tested one specific capsule-based FMT protocol in a VA population, and it found no advantage over placebo on either the infection itself or on how patients said they felt. That is different from saying FMT never helps: two newer, FDA-approved fecal microbiota products, Rebyota and Vowst, were shown in their own separate clinical trials to reduce recurrence and improve quality of life at eight weeks. The study's authors point to this contrast directly, noting that these newer products "have demonstrated clinical efficacy and also an improvement in health-related quality of life," something this trial's capsule regimen did not replicate. The practical takeaway is not that fecal transplants are ineffective as a category, but that formulation, delivery method, and trial design all appear to matter more than a single early success story would suggest, and that is worth raising directly with a physician rather than assuming any FMT-based product is interchangeable with another.

Limitations: A Preprint, a Secondary Endpoint, and a Null Result

Three caveats matter here. First, this is a preprint posted on Research Square in September 2026; it has not yet been peer-reviewed, so the specific numbers and conclusions could shift during that process. Second, quality of life was a pre-specified secondary, exploratory endpoint in a trial designed primarily to test infection recurrence, not the study's main question, so it was not necessarily powered to detect smaller quality-of-life differences. Third, and most simply, this is a null result: the confidence interval around the main quality-of-life comparison (-11.1 to 1.8) is wide enough that a true difference in either direction cannot be fully ruled out, even though the trial's own conclusion is that FMT showed neither improvement nor worsening of quality of life compared with placebo. The authors themselves note it is unclear whether even the numeric changes seen were large enough to be clinically meaningful, since some prior research treats a change of 10 or more points as the threshold for real-world significance.

What Comes Next for FMT Research

The authors call this the first study to test FMT's effect on quality of life within a blinded, placebo-controlled randomized trial for recurrent C. diff, and they frame it as an argument for treating patient-reported outcomes as a standard companion to clinical cure rates in future FMT trials, not an afterthought. The next steps will likely include peer review of this preprint, continued follow-up on real-world quality-of-life data from the newer FDA-approved products, and further scrutiny of why blinded, placebo-controlled FMT trials have increasingly produced weaker results than the earlier open-label studies that built the treatment's reputation in the first place.

Common Questions

Does this mean fecal transplants don't work for C. diff? Not as a blanket statement. This specific capsule-based protocol tested in the VA trial did not outperform placebo on recurrence or quality of life, but two other FDA-approved fecal microbiota products showed benefits on both measures in their own trials, so formulation and delivery method appear to matter.

What is the Gastrointestinal Quality of Life Index? It is a validated patient-reported questionnaire that scores how gut symptoms affect a person's physical, emotional, social, and daily functioning, with higher scores indicating better quality of life.

Is this preprint peer-reviewed? No. It was posted in September 2026 on the preprint server Research Square and has not yet completed formal peer review, so its findings could be revised.

Should I still consider FMT if I have recurrent C. diff? Talk with a doctor about the specific product and evidence behind it. This trial does not show that FMT is harmful, only that this particular capsule regimen did not measurably improve quality of life more than a placebo in a rigorous, blinded setting.

References

1. Aasma Shaukat, Yuan Huang, Dimitri Drekonja, et al. (2026). Quality of Life assessment among participants with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation versus placebo in a randomized clinical trial. https://doi.org/10.21203/rs.3.rs-10371678/v1
2. (2025). Correction to: A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf032
3. Jennifer Moisi (2022). Clostridioides difficile-Infection (CDI). VacciTUTOR. https://doi.org/10.33442/vt202159
4. FDA Approves First Fecal Microbiota Product. fda.gov. https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product
5. FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection. fda.gov. https://www.fda.gov/news-events/press-announcements/fda-approves-first-orally-administered-fecal-microbiota-product-prevention-recurrence-clostridioides